Amgen Inc. (AMGN)
NASDAQ: AMGN · Real-Time Price · USD
306.58
-1.97 (-0.64%)
At close: Jul 25, 2025, 4:00 PM
307.00
+0.42 (0.14%)
After-hours: Jul 25, 2025, 7:14 PM EDT
Amgen Revenue
Amgen had revenue of $8.15B in the quarter ending March 31, 2025, with 9.43% growth. This brings the company's revenue in the last twelve months to $34.13B, up 15.56% year-over-year. In the year 2024, Amgen had annual revenue of $33.42B with 18.57% growth.
Revenue (ttm)
$34.13B
Revenue Growth
+15.56%
P/S Ratio
4.83
Revenue / Employee
$1,218,786
Employees
28,000
Market Cap
164.85B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 33.42B | 5.23B | 18.57% |
Dec 31, 2023 | 28.19B | 1.87B | 7.09% |
Dec 31, 2022 | 26.32B | 344.00M | 1.32% |
Dec 31, 2021 | 25.98B | 555.00M | 2.18% |
Dec 31, 2020 | 25.42B | 2.06B | 8.83% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
Novartis AG | 55.19B |
AstraZeneca | 54.98B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
AMGN News
- 4 days ago - Dow Leads as Health Care Stocks Merck and Amgen Gain: Stock Market Today - Kiplinger
- 5 days ago - NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer - GlobeNewsWire
- 8 days ago - Undercovered Dozen: Christian Dior, Coca-Cola, Trinity Capital, Amgen And More - Seeking Alpha
- 11 days ago - Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns - Seeking Alpha
- 11 days ago - Amgen: Great Starting Yield For This Wealth Compounder - Seeking Alpha
- 17 days ago - Amgen: A Defensive Biotech With Yield And Optionality - Seeking Alpha
- 26 days ago - Amgen's gastric cancer drug meets late-stage trial goal - Reuters
- 26 days ago - AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER - PRNewsWire